Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Janssen-Cilag

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

- PMLiVE

Novartis acquires DTx Pharma in deal worth up to $1bn

The agreement gives Novartis access to three preclinical neuroscience programmes

EU flag

EU establishes €100m funding scheme for projects tackling public health threats

The HERA Invest fund will focus on health emergency prevention and preparedness initiatives

- PMLiVE

Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Pfizer reports positive results for elranatamab in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links